Home / Health / India's Pharma Watchdog Leaps to 8th Globally
India's Pharma Watchdog Leaps to 8th Globally
2 Jan
Summary
- India ranks 8th globally in WHO pharmacovigilance contributions, up from 123rd.
- The 10th edition of Indian Pharmacopoeia 2026 includes 121 new drug monographs.
- New standards cover critical areas like anti-cancer, anti-diabetic, and transfusion medicine.
India has achieved a remarkable ascent in global pharmacovigilance, moving from 123rd to 8th position in contributions to the World Health Organization's database. This progress was announced during the unveiling of the Indian Pharmacopoeia 2026, the country's tenth official compendium of drug standards.
The Indian Pharmacopoeia 2026 incorporates 121 new monographs, bringing the total to 3,340. It significantly strengthens standards for vital therapeutic categories such as anti-tubercular, anti-diabetic, and anti-cancer medications, alongside iron supplements, ensuring enhanced quality for drugs used in national health programs.
This edition also introduces 20 new monographs for blood components, marking a first for transfusion medicine standards. The Indian Pharmacopoeia's standards are increasingly recognized internationally, with acceptance in 19 countries in the global South, underscoring India's growing influence in pharmaceutical regulation and patient safety.
